StockpollyBeta
Get App
Popularity #2,689
CATX · AMEX · Medical - Devices

Perspective Therapeutics (CATX)

Develops image-guided lead-212 cancer therapies with paired lead-203 imaging.

$3.01
After hours+0.05 (+1.86%)
At close$2.96(−0.51%)

In millions of USD, except per-share figures

In millionsQ4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue−50000000000
Cost of revenue00000111010
Gross profit−5000000−10−10
310131945182427402729
Research & development6571213111220332022
24678788778
Selling & marketing−30000000000
General & administrative40078088778
Other expenses−50002404−1000
Operating income−8−10−13−19−45−19−24−28−40−28−29
−10143422222
Interest income00143422222
Interest expense00000000000
Other non-operating income100−4−30−2−2−20−3
Income before tax−9−10−12−15−42−15−22−26−38−26−27
Income tax expense8000−2000−100
Net income from continuing operations−17−10−12−15−40−15−22−26−37−26−27
Discontinued operations0−1000010000
Other adjustments−80000000000
Net income−25−10−12−15−40−15−21−26−37−26−27
EPS, basic−$0.18−$0.20−$0.25−$0.21−$0.60−$0.21−$0.30−$0.35−$0.50−$0.35−$0.36
EPS, diluted−$0.18−$0.37−$0.25−$0.21−$18.84−$0.21−$0.30−$0.35−$0.50−$0.35−$0.36
Weighted average shares, basic6752507167717174747474
Weighted average shares, diluted672850712717174747474
EBITDA−9−10−13−14−42−18−21−25−37−27−27
Depreciation & amortization00011111110
EBIT−9−10−13−15−42−19−22−26−38−28−27